All In Biotech

Drug Trial Radar · NCT05529992

A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease

A Multicenter, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Velaglucerase Alfa in Chinese Subjects With Type 1 Gaucher Disease

Last checked: Nov 19, 2026Latest source record: Jun 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

20

Actual

Start

Jan 3, 2023

Primary completion

Aug 5, 2024

Study completion Aug 5, 2024

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Sep 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to observe the side effects of VPRIV in participants with type 1 Gaucher disease who are either treatment-naïve (newly diagnosed) or who are currently being treated with enzyme replacement therapy (ERT). Participants will receive VPRIV intravenously during the treatment period (up to 51 weeks), followed by the end-of-treatment (EOT) visit after 2 weeks.

Conditions

  • Gaucher Disease

Interventions

  • Velaglucerase AlfaDrug

    VPRIV intravenous infusion every other week for 60 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With at Least One Serious Treatment-Emergent Adverse Event (TEAE)Time frame: Up to 56.2 weeks

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

  • Beijing Children's Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Guangzhou Women and Children's Medical Center

    Guangzhou, Guangdong, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Nanjing Children's Hospital

    Nanjing, Jiangsu, China

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.